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Letters to the Editorand only for patients presenting with a
coagulopathy as confirmed by rota-
tional thromboelastometric analysis.
Ideally, the lowest dose capable
of correcting the coagulopathy should
be given, avoiding a hypercoagulable
state and thus thromboembolic events.
Adopting this protocol avoids placing
patients with a surgical cause of
bleeding at an unjustified risk of
thromboembolism and reserves rFVIIa
for thosewho truly need it.
In conclusion, rFVIIa represents
a treatment with its own specific indi-
cations, and we should not consider it
as an alternative to reexploration in
cardiac surgery. Indeed, the two are
‘‘horses for courses.’’
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WeappreciateTarzia andcolleagues’
letter regarding our article.1 They take
exception to comparing reexploration
with pharmacologic management us-
ing recombinant activated factor VII
(rFVIIa) in the intensive care unit be-
cause the source of bleeding is not
known. They also elucidate a well–
thought out algorithm for the manage-
ment of postoperative bleeding.
Our initial experience with rFVIIa
was in the operating room, where we
found it to be highly effective at con-
trolling intraoperative bleeding and
to reduce the incidence of packing
and delayed closure for hemostasis.2
We developed criteria for correction
of coagulopathy (including platelet
count, prothrombin time, partial
thromboplastin time, and fibrinogen
levels), acid–base status, temperature,
and ionized calcium levels before the
administration of rFVIIa. We found
that patients who continued to bleed
despite correction of these variables
responded quickly to rFVIIa.
All intensive care unit patients in our
current study had undergone similar
evaluations in the operating room and
were considered not to have surgical
bleeding. Unfortunately, the source of
significant bleeding in the intensive
care unit is always unknown, and this
is the clinical conundrum our study at-
tempted to address. In this study, we
found 1 case of surgical bleeding out
of the 12 patients who received rFVIIa.
This is substantially lower than the
50% quoted by Tarzia and colleagues.
This emphasizes the importance of
having a well–thought out algorithm
for the management of bleeding. Ours
begins by defining significant bleeding
as 3 mL/kg/h for 2 or more consecutive
hours. Correction of the previously
mentioned variables is accomplished
as early as possible. Hemothorax and
pericardial tamponade are considered
indications for reoperation. Finally,
the attending surgeon’s index of suspi-
cion for surgical bleeding is the final
determinant of therapy. As we hadof Thoracic and Cardiovascular Surgerpreviously observed in the operating
room, bleeding intensive care unit pa-
tients with corrected coagulation fac-
tors, temperature, ionized calcium,
and acidosis quickly responded to
rFVIIa.This suggests thatwe are not ca-
pable of measuring a clinically signifi-
cant coagulation deficiency. Perhaps
rotational thromboelastometry will be
able to shed light on these difficult pa-
tients. Rotational thromboelastometry
was only recently approved by the
Food and Drug Administration in 2010
(after our study period), and further-
more only 2 of the 4 reagents described
by Tarzia and colleagues, INTEM and
HEPTEM, have been approved.
We anxiously await new tools for
the diagnosis and treatment of postop-
erative coagulopathic bleeding. It is
important that they be incorporated
into a well-designed and well–thought
out algorithm for the treatment of
postoperative bleeding.
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To the Editor:
We read with great interest the re-
cent published paper by Shi andy c Volume 142, Number 6 1589
